Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus
- 1 September 2002
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 20 (3) , 220-222
- https://doi.org/10.1016/s0924-8579(02)00132-2
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteriaInternational Journal of Antimicrobial Agents, 2001
- Linezolid resistance in a clinical isolate of Staphylococcus aureusThe Lancet, 2001
- Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 2001
- Therapeutic Efficacy of GAR-936, a Novel Glycylcycline, in a Rat Model of Experimental EndocarditisAntimicrobial Agents and Chemotherapy, 2000
- In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniaeDiagnostic Microbiology and Infectious Disease, 2000
- Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?Journal of Antimicrobial Chemotherapy, 2000
- In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive BacteriaAntimicrobial Agents and Chemotherapy, 2000
- Antipneumococcal Activities of GAR-936 (a New Glycylcycline) Compared to Those of Nine Other Agents against Penicillin-Susceptible and -Resistant PneumococciAntimicrobial Agents and Chemotherapy, 2000
- In-vitro susceptibility of anaerobic bacteria to gar-936, a new glycylcyclineClinical Microbiology & Infection, 2000
- Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclinesAntimicrobial Agents and Chemotherapy, 1994